The Silent Epidemic: Why Vaginal and Vulvar Cancers Deserve More Attention
There’s a quiet crisis lurking in the shadows of women’s health, and it’s one that doesn’t get nearly enough attention. Vaginal and vulvar cancers, though rare, carry a staggering survival disparity compared to more common cancers like breast or endometrial. Personally, I think this is one of those issues that highlights the gaps in our healthcare system—gaps that disproportionately affect women, especially those in marginalized communities. What makes this particularly fascinating is how these cancers, despite their rarity, reveal systemic challenges in diagnosis, awareness, and care.
The Numbers Don’t Lie—But They Only Tell Half the Story
Let’s start with the facts: the five-year survival rates for vaginal and vulvar cancers are 53% and 74%, respectively. Compare that to breast cancer’s 93% or endometrial cancer’s 84%, and the disparity is glaring. But here’s where it gets even more troubling: in Australia, there were only 117 new cases of vaginal cancer and 401 cases of vulvar cancer in 2025. That rarity is part of the problem. Clinicians, especially general practitioners, might go their entire careers without encountering a single case. From my perspective, this rarity breeds unfamiliarity, and unfamiliarity breeds misdiagnosis or delayed treatment.
What many people don’t realize is that these cancers are often asymptomatic in their early stages, making them incredibly difficult to catch without proactive screening. And unlike cervical cancer, which has well-established screening programs, vaginal and vulvar cancers lack dedicated early detection methods. If you take a step back and think about it, this is a recipe for late-stage diagnoses and poorer outcomes.
Guidelines Exist—But Are They Enough?
Here’s where things get interesting: guidelines for prevention and diagnosis do exist, but they’re far from perfect. A recent systematic review identified 45 international guidelines, with only two developed in Australia. While these guidelines recommend HPV vaccination, opportunistic screening, and biopsies for suspicious lesions, they fall short in several critical areas.
One thing that immediately stands out is the lack of consumer input. Few guidelines incorporate the perspectives of those with lived experience, which is baffling. In my opinion, this oversight perpetuates inequities, particularly for priority groups like Aboriginal and Torres Strait Islander people, rural populations, and older Australians. What this really suggests is that even well-intentioned guidelines can fail if they’re not culturally sensitive or practically applicable.
Another detail that I find especially interesting is the low applicability of these guidelines. They often lack clear implementation strategies, resource considerations, or methods for monitoring uptake. It’s like handing someone a map without telling them how to read it. This raises a deeper question: if guidelines aren’t actionable, what good are they?
The Case for Optimal Care Pathways (OCPs)
This is where OCPs come in—a concept that could be a game-changer. OCPs provide standardized, evidence-based care pathways that have proven effective for cancers like colorectal. Personally, I think the absence of an OCP for vaginal and vulvar cancers is a missed opportunity. An OCP could address the limitations of current guidelines by incorporating consumer perspectives, providing clear timeframes for diagnosis, and offering practical implementation advice.
But here’s the catch: developing an OCP isn’t just about compiling evidence. It’s about addressing the psychological, cultural, and logistical barriers that prevent women from accessing care. For instance, self-collection for HPV screening, while effective for reaching underserved populations, reduces opportunities for incidental findings during physical exams. This trade-off is rarely discussed, but it’s crucial for understanding the broader implications of our screening strategies.
The Broader Implications: A System in Need of Reform
If you ask me, the challenges surrounding vaginal and vulvar cancers are symptomatic of a larger issue: our healthcare system’s struggle to address rare diseases. Rare cancers often fall through the cracks because they’re not profitable to research or treat. But rarity doesn’t diminish the human cost. Every missed diagnosis, every delayed treatment, represents a life impacted—often irreversibly.
What this really suggests is that we need a paradigm shift. We need to prioritize equity, accessibility, and inclusivity in healthcare. We need to invest in education for clinicians, awareness campaigns for the public, and research that centers the experiences of marginalized communities. And we need to stop treating rare cancers as afterthoughts.
Final Thoughts: A Call to Action
As I reflect on this issue, I’m struck by how much work remains to be done. Vaginal and vulvar cancers may be rare, but their impact is profound. They’re a stark reminder of the gaps in our healthcare system—gaps that we can, and must, address.
In my opinion, the first step is simple: start talking about it. Raise awareness, advocate for better guidelines, and push for the development of OCPs. Because at the end of the day, no woman should face a cancer diagnosis without the support, resources, and care she deserves.
What many people don’t realize is that change starts with conversations like this. So let’s keep talking—and let’s keep fighting for a healthcare system that leaves no one behind.
